https://ellipses.life

Ellipses Pharma | Oncology-Focused Drug Development CompanyEllipses Pharma is a revolutionary oncology-focused drug development company. Accelerating cancer treatment discoveries for unmet clinical needs. Find out how.Ellipses Pharma | Oncology-Focused Drug Development Company MenuAboutABOUTWhat we doLeadershipScientific Affairs GroupPortfolioNewsContact About What we do Leadership Scientific Affairs Group Portfolio News Contact Your browser does not support the video tag. Your browser does not support the video tag. WE ARE A PRECISION DRUG DEVELOPMENT COMPANY FOCUSED ON ONCOLOGY Our purpose is to accelerate the development of cancer medicines and treatments View our portfolio Rewriting Cancer We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients. Talk to our team We’d like to hear from you Contact us Read the latest news from Ellipses Pharma EP0031 poster presented at ESMO 2024EP0031 (A440/KL590586), a promising next generation selective RET inhibitor (SRI) presented at ESMO 2024 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1726227477049%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2024%252F09%252FESMO_2024_Poster_Sept24_final.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset [...]Read moreKey opinion leaders and their role in oncology researchThe innovative use of key opinion leaders in oncology research to improve the clinical trials landscape In the summer 2024 issue of International Clinical Trials, Ellipses Pharma’s Head of Global Drug Development Professor Tobi Arkenau discusses our unique approach to using Ellipses’ unique Scientific Affairs Group to overcome challenges in oncological clinical trials. Read the [...]Read moreEP0031 poster presented at ASCO 2024Phase 1 study data for EP0031/A400, presented at ASCO 2024 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1717506230986%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2024%252F05%252FASCO_2024_Poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted [...]Read more About Portfolio News Contact Contact Us | Careers | Privacy Policy | Expanded Access Policy | Cookie Policy LinkedIn © 2024 Ellipses Pharma Ellipses Pharma is a registered trademark of Ellipses Pharma Limited. Ellipses, Ellipses Pharma, and the Ellipses Pharma logo are trademarks of Ellipses Pharma Limited.engben-GB1729150021https://ellipses.life

Edit your site?

What are you doing?